492.69
-9.86 (-1.96%)
| 前收盘价格 | 502.55 |
| 收盘价格 | 504.79 |
| 成交量 | 1,246,811 |
| 平均成交量 (3个月) | 1,450,556 |
| 市值 | 126,517,862,400 |
| 预期市盈率 (P/E Forward) | 30.12 |
| 价格/销量 (P/S) | 11.99 |
| 股市价格/股市净资产 (P/B) | 8.02 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -4.86% |
| 营业利益率 (TTM) | 44.98% |
| 稀释每股收益 (EPS TTM) | -2.10 |
| 季度收入增长率 (YOY) | 15.70% |
| 季度盈利增长率 (YOY) | -5.80% |
| 总债务/股东权益 (D/E MRQ) | 10.66% |
| 流动比率 (MRQ) | 2.69 |
| 营业现金流 (OCF TTM) | -492.60 M |
| 杠杆自由现金流 (LFCF TTM) | 2.73 B |
| 资产报酬率 (ROA TTM) | 12.68% |
| 股东权益报酬率 (ROE TTM) | -3.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Vertex Pharmaceuticals Incorpor | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 0.11% |
| 机构持股比例 | 96.58% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Loomis Sayles & Co L P | 31 Dec 2024 | 3,772,789 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 567.00 (B of A Securities, 15.08%) | 购买 |
| 中 | 467.00 (-5.21%) | |
| 低 | 420.00 (RBC Capital, -14.75%) | 保留 |
| 平均值 | 484.55 (-1.65%) | |
| 总计 | 5 购买, 6 保留 | |
| 平均价格@调整类型 | 459.29 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 01 Apr 2025 | 420.00 (-14.75%) | 保留 | 492.69 |
| 20 Feb 2025 | 408.00 (-17.19%) | 保留 | 480.33 | |
| B of A Securities | 31 Mar 2025 | 567.00 (15.08%) | 购买 | 492.69 |
| Canaccord Genuity | 12 Feb 2025 | 424.00 (-13.94%) | 保留 | 453.20 |
| Barclays | 11 Feb 2025 | 467.00 (-5.21%) | 保留 | 455.22 |
| Cantor Fitzgerald | 11 Feb 2025 | 480.00 (-2.58%) | 购买 | 455.22 |
| 31 Jan 2025 | 480.00 (-2.58%) | 购买 | 461.68 | |
| HC Wainwright & Co. | 11 Feb 2025 | 550.00 (11.63%) | 购买 | 455.22 |
| 31 Jan 2025 | 550.00 (11.63%) | 购买 | 461.68 | |
| Morgan Stanley | 11 Feb 2025 | 459.00 (-6.84%) | 保留 | 455.22 |
| Scotiabank | 11 Feb 2025 | 450.00 (-8.66%) | 保留 | 455.22 |
| 31 Jan 2025 | 433.00 (-12.12%) | 保留 | 461.68 | |
| Truist Securities | 11 Feb 2025 | 520.00 (5.54%) | 购买 | 455.22 |
| Wells Fargo | 30 Jan 2025 | 460.00 (-6.64%) | 保留 | 438.40 |
| 10 Jan 2025 | 460.00 (-6.64%) | 购买 | 409.56 | |
| Piper Sandler | 27 Jan 2025 | 533.00 (8.18%) | 购买 | 443.88 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合